



PATENT  
Customer No. 22,852  
Attorney Docket No. 03495.0217-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Schwartz et al. ) Group Art Unit: 1614  
Application No.: 10/083,678 ) Examiner: Not yet assigned  
Filed: February 27, 2002 )  
For: MHC-I-RESTRICTED PRESENTATION OF HIV-1 VIRION ANTIGENS  
WITHOUT VIRAL REPLICATION. APPLICATION TO THE STIMULATION  
OF CTL AND VACCINATION *IN VIVO*; ANALYSIS OF VACCINATING  
COMPOSITION *IN VITRO*

RECEIVED

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

JAN 20 2004

Sir:

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the copending application listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits.

A copy of the listed application is attached.

Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and applicants determine that the cited document does not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 3, 2003

By: \_\_\_\_\_


  
\_\_\_\_\_  
Salvatore J. Arrigo  
Reg. No. 46,063  
Phone: (202) 408-4160  
Fax: (202) 408-4400  
E-mail: arrigos@finnegan.com

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03495.0217-00	Appln. No.	10/083,678
Applicant	Schwartz et al.		
Filing Date	February 27, 2002	Group:	1614



## U.S. PATENT DOCUMENTS

RECEIVED

JAN 20 2004

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Schwartz et al., "MHC-I-Restricted presentation of HIV-1 virion antigens without viral replication. Application to the stimulation of CTL and vaccination *in vivo*; analysis of vaccinating composition *in vitro*," Specification of U.S. Appln. No. 10/468,765, filed August 21, 2003 ✓

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	